Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: Review of a pivotal trial

Future Oncology

Volumn 7, Issue 1, 2011, Pages 9-14

  Ujjani, Chaitra ^a   Cheson, Bruce ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

antimetabolite; chronic lymphocytic leukemia; non Hodgkin's lymphoma; rituximab refractory; Treanda

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HERPES ZOSTER; HUMAN; INFECTION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT INFECTION; SEPSIS; SEPTIC SHOCK; SINUSITIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 78650622872     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.169     Document Type: Article

References (16)

1. Hallek M, Fingerle-Rowson G, Fink A et al.: Immunochemotherapy with fudarabine, cyclophosphamide and rituximab (FCR) versus fudarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 112, 325 (2008).
2. Byrd JC, Peterson BL, Morrison VA et al.: Randomized Phase II study of fudarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712). Blood. 101, 6-14 (2003).
3. Van Oers MH, Klasa R, Marcus RE et al.: Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin's lymphoma in patients with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood 108, 3295-3301 (2006).
4. Pfreundschuh M, Trümper L, Osterborg A et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-391 (2006).
5. Ozegowski W, Krebs D: IMET 3393, (-[1-methyl-5-bis-(2-chloroethyl)-amino- benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl Pharm. 110, 1013-1019 (1971).
6. Leoni LM, Bailey B, Reifert J et al.: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309-317 (2008).
7. Knauf WU, Lissichkov T, Aldaoud A et al.: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4378-4384 (2009).
8. Friedberg JW, Cohen P, Chen L et al.: Bendamustine in patients with rituximab? refractory and alkylator-refractory, indolent, and transformed non-Hodgkin's lymphoma: Results from a Phase II multicenter single-agent study. J. Clin. Oncol. 26, 204-210 (2008).
9. Heider A, Niederle N: Effcacy and toxicity of bendamustine in patients with relapsed low-grade nonHodgkin's lymphomas. Anticancer Drugs. 12, 725-729 (2001).
10. Bremer K: High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade non-Hodgkin's lymphomas. J. Cancer Res. Clin. Oncol. 128, 603-609 (2002).
11. Kahl B, Bartlett NL, Leonard JP et al.: Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Blood (ASH Annual Meeting). 110, 11 (2007) (Abstract 1351).
12. Kahl B, Bartlett NHL, Leonard JP et al.: Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study Cancer 116, 106-114 (2010).
13. Cheson BD, Pfstner B, Juweid ME et al.: Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25(5), 579-586 (2007).
14. Rummel M, Niederle N, Maschmeyer G et al.: Bendamustine plus rituximab is superior in respect of progression-free survival and CR rate when compared to CHOP plus rituximab as frst-line treatment of patients with advanced follicular, indolent, and mantle cell lymphoma: fnal results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting). 114 (2009) (Abstract 405).
15. Hiddemann W, Buske C, Kneba M et al.: Autologous stem cell transplantation after myeloablative therapy in frst remission may be benefcial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of two consecutive studies of the German Low Grade Lymphoma Study Group (GLSG). Blood (ASH Annual Meeting). 112 (2008) (Abstract 772).
16. Salles G, Seymour J, Feugier P et al.: Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy J. Clin. Oncol. (ASCO Meeting Abstracts) 28 (2010) (Abstract 8004).